Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 1/2018

01-02-2018 | Original Paper

Efficacy of systemic diclofenac sodium on intravitreal concentration

Authors: Yunes Panahi, Mostafa Naderi, Khosrow Jadidi, Hadise Hoseini, Mojtaba Abrishami

Published in: International Ophthalmology | Issue 1/2018

Login to get access

Abstract

Background

Nonsteroidal anti-inflammatory drugs (NSAIDs), as an alternative, are replacing corticosteroids in ocular inflammatory diseases. Diclofenac has been used mainly topically, and recent focus has been on intravitreal delivery. Both of these methods have been shown to have complications in long-term application.

Purpose

To assess the efficacy of slow release oral diclofenac sodium on intravitreal concentration in experimental model of chemically injured eyes.

Methods

In an experimental double-masked clinical trial, right eyes of 24 albino rabbits were chemically injured by 1 N NaOH. One hour after chemical injury, 10 cc suspension gavage containing 100 mg slow release diclofenac sodium was administered in all cases. 2, 4, 6, 12, 24, 48 h after gavage, vitreous samples were obtained in all cases. Intravitreal concentration of diclofenac sodium was evaluated in all samples using high-performance liquid chromatography (HPLC) method.

Results

Intravitreal diclofenac levels by oral intake were enhanced by the inflammation in all the measurements. In inflamed eyes, diclofenac concentration was ten times more than control eye (2.658 ± 0.344 vs. 0.242 ± 0.0279 and 1.617 ± 0.527 vs. 0.148 ± 0.095; in 2 and 4 h, respectively). After 6 h, diclofenac concentration was statistically different, although it reduced below 1 μg/ml.

Conclusion

Diclofenac is delivered to the inflamed eye more than healthy eye. It seems that by oral diclofenac consumption, it is possible to make a significant intravitreal concentration.
Literature
1.
Leung TG, Thorne JE (2013) Emerging drugs for the treatment of uveitis. Expert Opin Emerg Drugs 18(4):513–521CrossRefPubMed
2.
3.
4.
Pan J, Kapur M, McCallum R (2014) Noninfectious immune-mediated uveitis and ocular inflammation. Curr Allergy Asthma Rep 14(1):409CrossRefPubMed
5.
Jonas JB, Kreissig I, Sofker A, Degenring RF (2003) Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57–61CrossRefPubMed
6.
Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM (2005) Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 112:139–143CrossRefPubMed
7.
Flach AJ (2002) Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 42:1–11CrossRefPubMed
8.
Monnier Y, Zaric J, Ruegg C (2005) Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy 4:31–38CrossRefPubMed
9.
Amrite AC, Edelhauser HF, Kompella UB (2008) Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Investig Ophthalmol Vis Sci 49:320–332CrossRef
10.
Costagliola C, Parmeggiani F, Antinozzi PP, Caccavale A, Cotticelli L, Sebastiani A (2005) The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp Eye Res 81:610–615CrossRefPubMed
11.
Rabiah PK, Fiscella RG, Tessler HH (1996) Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci 37:613–618PubMed
12.
Davies NM, Anderson KE (1997) Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet. 33(3):184–213PubMed
13.
Soheilian M, Karimi S, Ramezani A, Peyman GA (2010) Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 30(3):509–515CrossRefPubMed
14.
Soheilian M, Karimi S, Ramezani A, Montahai T, Yaseri M, Soheilian R, Peyman GA (2015) Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial. Int Ophthalmol 35(3):421–428CrossRefPubMed
15.
Elbendary AM, Shahin MM (2011) Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Retina 31(10):2058–2064CrossRefPubMed
16.
Soheilian M, Eskandari A, Ramezani A, Rabbanikhah Z, Soheilian R (2013) A pilot study of intravitreal diclofenac versus intravitreal triamcinolone for uveitic cystoid macular edema. Ocul Immunol Inflamm 21(2):124–129CrossRefPubMed
17.
Ramezani A, Fard Esmaeilpour N, Eskandari A, Rabbanikhah Z, Soheilian R, Soheilian M (2013) Intravitreal diclofenac for refractory uveitic cystoid macular edema. J Ophthalmic Vis Res 8(1):47–52PubMedCentralPubMed
18.
Tutton MK, Cherry PMH, Raj PS, Fsadni MG (1996) Efficacy and safety of topical diclofenac in reducing ocular pain after excimer photorefractive keratectomy. J Cataract Refract Surg 22:536–541CrossRefPubMed
19.
Weinstock VM, Weinstock DJ, Weinstock SJ (1996) Diclofenac and ketorolac in the treatment of pain after photorefractive keratectomy. J Refract Surg 12:792–794PubMed
20.
Caldwell M, Reilly C (2008) Effects of topical nepafenac on corneal epithelial healing time and postoperative pain after PRK: a bilateral, prospective, randomized, masked trial. J Refract Surg 24:377–382PubMed
21.
Donnenfeld ED, Holland EJ, Durrie DS, Raizman MB (2007) Double masked study of the effects of nepafenac 0.1% and ketorolac 0.4% on corneal epithelial wound healing and pain after photorefractive keratectomy. Adv Ther 24:852–862CrossRefPubMed
22.
23.
Donnenfeld ED, Donnenfeld A (2006) Global experience with xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin 46(4):21–40CrossRefPubMed
24.
Flach AJ, Jaffe NS, Akers WA (1989) The effect of ketorolac tromethamine in reducing postoperative inflammation: double-mask parallel comparison with dexamethasone. Ann Ophthalmol 21:407–411PubMed
25.
Mochizuki M, Sawa M, Masuda K (1977) Topical indomethacin in intracapsular extraction of senile cataract. Jpn J Ophthalmol 21:215–226
26.
Dahl JB, Kehlet H (1993) The value of pre-emptive analgesia in the treatment of postoperative pain. Br J Anaesth 70:434–439CrossRefPubMed
27.
Savage MG, Henry MA (2004) Preoperative nonsteroidal anti-inflammatory agents: review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:146–152CrossRefPubMed
28.
El-Harazi SM, Ruiz RS, Feldman RM, Villanueva G, Chuang AZ (2000) Efficacy of preoperative versus postoperative ketorolac tromethamine 0.5% in reducing inflammation after cataract surgery. J Cataract Refract Surg 26:1626–1630CrossRefPubMed
29.
Flach AJ, Lavelle CJ, Olander KW, Retzlaff JA, Sorenson LW (1988) The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology 95:1279–1284CrossRefPubMed
30.
Eslampoor A, Ehsaei A, Abrishami M (2014) Effect of topical diclofenac on postoperative photorefractive keratectomy pain: a randomized, controlled trial. Clin Exp Ophthalmol 42(9):810–814CrossRefPubMed
31.
Eslampour A, Malaekeh-Nikouei B, Abrishami M, Bayani R (2013) Efficacy of extended-release oral diclofenac in postoperative pain management after photorefractive keratectomy. J Ocul Pharmacol Ther 29(7):670–673CrossRefPubMed
32.
Durairaj C, Kim SJ, Edelhauser HF, Shah JC, Kompella UB (2009) Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci 50(10):4887–4897CrossRefPubMedCentralPubMed
Metadata
Title
Efficacy of systemic diclofenac sodium on intravitreal concentration
Authors
Yunes Panahi
Mostafa Naderi
Khosrow Jadidi
Hadise Hoseini
Mojtaba Abrishami
Publication date
01-02-2018
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 1/2018
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-016-0428-8

Other articles of this Issue 1/2018

International Ophthalmology 1/2018 Go to the issue

Original Paper

Changing trend in referral to secondary care specialist thyroid eye disease clinic following the Amsterdam declaration

Original Paper

Management of sulcus-fixated single-piece intraocular lens-induced pigmentary glaucoma with 3-piece IOL exchange

Original Paper

Changes in choroidal thickness in patients with diabetic retinopathy

Original Paper

Assessing posterior ocular structures in β-thalassemia minor

Case Report

Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome

Review

Pathophysiology, diagnosis, and management of glaucoma associated with Sturge–Weber syndrome